Cancer molecular subtyping using limited multi-omics data with missingness
Fig 5
Important molecules identified by CancerSD.
(a) Importance scores of the top-ranked molecules identified by CancerSD in various omics.(b) Differences in the importance scores of molecules across various omics.(c) Clustering for samples of different subtypes using omics embeddings and fusion representation output by CancerSD, respectively.(d) The methylation levels of the top 100 CpG sites ranked by importance, where the CpG sites are secondary sorting based on the average values across all samples.(e) The expression levels of mRNA characteristics across different GC subtypes.(f) The expression levels of mRNA and miRNA characteristics across different GC subtypes, where the expression values subjected to log2 transformation and normalization. Wilcoxon rank-sum test is employed to evaluate the differences in the expression levels of specific molecules among patients of distinct subtypes.(g) Gene co-expression analysis result for EBV subtype.(h) KEGG Pathway Enrichment results for module-2 (ME-2, top) and module-4 (ME-4, bottom), respectively.